Holen Sie sich die Stockscreener-App
12.23
4.09%
0.48
Handel nachbörslich:
11.99
-0.24
-1.96%
Schlusskurs vom Vortag:
$11.75
Offen:
$11.93
24-Stunden-Volumen:
203.40K
Relative Volume:
1.67
Marktkapitalisierung:
$104.19M
Einnahmen:
$153.73M
Nettoeinkommen (Verlust:
$-106.79M
KGV:
-6.8708
EPS:
-1.78
Netto-Cashflow:
$-115.93M
1W Leistung:
+11.59%
1M Leistung:
+44.05%
6M Leistung:
+55.58%
1J Leistung:
-37.28%
1-Tages-Spanne:
$11.88
$13.30
1-Wochen-Bereich:
$10.15
$13.30
52-Wochen-Spanne:
$5.231
$21.50
Sutro Biopharma Inc Stock (STRO) Company Profile
Firmenname
Sutro Biopharma Inc
Sektor
Branche
Telefon
650-392-8412
Adresse
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Vergleichen Sie STRO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
STRO
Sutro Biopharma Inc
|
12.23 | 100.10M | 153.73M | -106.79M | -115.93M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-16 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-03-17 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-03-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-03-14 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-05-08 | Eingeleitet | BofA Securities | Buy |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-06 | Eingeleitet | Oppenheimer | Outperform |
| 2023-03-21 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-06-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-09-02 | Eingeleitet | Jefferies | Buy |
| 2020-07-16 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-10-07 | Eingeleitet | BTIG Research | Buy |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2019-04-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-10-22 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2018-10-22 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-10-22 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Sutro Biopharma Inc Aktie (STRO) Neueste Nachrichten
Why millennials buy Sutro Biopharma Inc. (S09) stockMarket Trend Report & Fast Exit and Entry Strategy Plans - ulpravda.ru
Is Sutro Biopharma Inc. stock supported by strong cash flowsJuly 2025 Analyst Calls & Capital Efficiency Focused Ideas - ulpravda.ru
Is Sutro Biopharma Inc. stock a buy for dividend growth2025 Bull vs Bear & Precise Buy Zone Identification - ulpravda.ru
Is Sutro Biopharma Inc. stock undervalued vs historical averagesProfit Target & Risk Controlled Daily Plans - ulpravda.ru
Will Sutro Biopharma Inc. stock benefit from sector rotationInflation Watch & Consistent Return Strategy Ideas - ulpravda.ru
How risky is Sutro Biopharma Inc. stock nowJuly 2025 News Drivers & AI Enhanced Trade Execution Alerts - ulpravda.ru
What momentum indicators show for Sutro Biopharma Inc. stockPortfolio Risk Summary & Free Safe Capital Growth Stock Tips - ulpravda.ru
Sutro Biopharma, Inc. to Present at 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026 - Quiver Quantitative
Sutro Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Sutro Biopharma lays off dozens of employees in ‘strategic portfolio review’ - MSN
Growth Report: What consensus target says about Sutro Biopharma Inc S09 stockQuarterly Trade Report & Risk Adjusted Buy and Sell Alerts - moha.gov.vn
Sutro Biopharma, Inc. (NASDAQ:STRO) Given Average Recommendation of “Hold” by Analysts - Defense World
Sutro Biopharma, Inc. (NASDAQ:STRO) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates - sharewise.com
Treasury Yields: Can Sutro Biopharma Inc stock beat analyst upgradesGlobal Markets & Growth Focused Entry Reports - moha.gov.vn
Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 46% - simplywall.st
Sutro Biopharma (NASDAQ:STRO) Will Have To Spend Its Cash Wisely - Yahoo Finance
Sutro Biopharma, Inc. (NASDAQ:STRO) Held Back By Insufficient Growth Even After Shares Climb 46% - 富途牛牛
Sutro Biopharma Stock Pre-Market (+6.9%): Momentum From Analyst EPS Upgrade - Trefis
Sutro Biopharma FY2025 EPS Forecast Boosted by HC Wainwright - Defense World
FY2025 EPS Estimate for Sutro Biopharma Increased by Analyst - MarketBeat
Sutro Biopharma, Inc. (NASDAQ:STRO) Short Interest Down 85.9% in December - MarketBeat
Sutro Biopharma (NASDAQ:STRO) Given New $10.00 Price Target at HC Wainwright - Defense World
HC Wainwright Forecasts Strong Price Appreciation for Sutro Biopharma (NASDAQ:STRO) Stock - MarketBeat
STRO: HC Wainwright Raises Price Target by 400% Today | STRO Sto - GuruFocus
HC Wainwright & Co. Maintains Sutro Biopharma (STRO) Neutral Recommendation - Nasdaq
Is Sutro Biopharma Inc. stock a contrarian buyQuarterly Trade Summary & High Accuracy Investment Entry Signals - Улправда
How rising interest rates impact Sutro Biopharma Inc. stockJuly 2025 Analyst Calls & Expert Verified Stock Movement Alerts - Улправда
Can Sutro Biopharma Inc. stock continue upward trendQuarterly Profit Report & Accurate Buy Signal Alerts - Улправда
Aug Rallies: Why Sutro Biopharma Inc stock is trending among retail tradersPortfolio Update Summary & Growth Oriented Trading Recommendations - moha.gov.vn
Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines - marketscreener.com
Why Sutro Biopharma Inc. (S09) stock benefits from AI revolutionM&A Rumor & Risk Controlled Daily Plans - DonanımHaber
Is Sutro Biopharma Inc. stock cheap at current valuationQuarterly Risk Review & Free Technical Pattern Based Buy Signals - DonanımHaber
Bear Alert: Is Sutro Biopharma Inc. stock a contrarian buyPortfolio Return Summary & AI Powered Market Entry Ideas - ulpravda.ru
Is Sutro Biopharma Inc. (S09) stock ideal for retirement investorsWeekly Trend Summary & Stepwise Entry and Exit Trade Signals - Улправда
Sutro Biopharma regains Nasdaq compliance after meeting minimum bid price - Investing.com Australia
Sutro Biopharma regains Nasdaq compliance after reverse stock split - Investing.com India
Sutro Biopharma regains Nasdaq compliance after meeting minimum bid price By Investing.com - Investing.com South Africa
Sutro Biopharma Regains Nasdaq Listing Compliance - TipRanks
Sutro Biopharma regains Nasdaq compliance after reverse stock split By Investing.com - Investing.com South Africa
Sutro Biopharma Regains Nasdaq Compliance - TradingView — Track All Markets
[8-K] SUTRO BIOPHARMA, INC. Reports Material Event | STRO SEC FilingForm 8-K - Stock Titan
Free cash flow per share of Sutro Biopharma, Inc. – MUN:S090 - TradingView — Track All Markets
Sutro Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement - The Manila Times
Sutro Biopharma Regains Nasdaq Compliance Following Reverse Stock Split - Quiver Quantitative
Deutsche Bank Boosts Price Target on Sutro Biopharma to $51 From $5, Keeps Buy Rating - marketscreener.com
CEO Chung Acquires 1,606 Of Sutro Biopharma Inc [STRO] - TradingView — Track All Markets
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates - MSN
Finanzdaten der Sutro Biopharma Inc-Aktie (STRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Sutro Biopharma Inc-Aktie (STRO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER |
Oct 15 '25 |
Buy |
0.80 |
17,000 |
13,607 |
71,832 |
| Chow Gregory K. | CFO |
Oct 15 '25 |
Buy |
0.81 |
19,750 |
15,998 |
19,750 |
| Chung Jane | Chief Executive Officer |
Oct 15 '25 |
Buy |
0.80 |
12,500 |
10,011 |
122,850 |
| MATSUI CONNIE | Director |
Oct 15 '25 |
Buy |
0.80 |
50,000 |
39,950 |
50,000 |
| Pauling David | Chief Admin. Ofcr. & GC |
Oct 15 '25 |
Buy |
0.80 |
12,504 |
9,993 |
71,737 |
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER |
Sep 18 '25 |
Option Exercise |
0.00 |
37,500 |
0 |
68,249 |
| Leyman Barbara | Chief Business Officer |
Jul 08 '25 |
Option Exercise |
0.00 |
25,000 |
0 |
25,000 |
| Chung Jane | Chief Executive Officer |
Aug 09 '25 |
Option Exercise |
0.00 |
18,750 |
0 |
117,058 |
| ALBINI EDWARD C | CFO AND SECRETARY |
May 15 '25 |
Option Exercise |
0.00 |
44,719 |
0 |
176,800 |
| FITZPATRICK LINDA A | CHIEF PEOPLE & COMM. OFFICER |
May 01 '25 |
Option Exercise |
0.00 |
37,849 |
0 |
133,282 |
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):